<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Infect. Dis</journal-id><journal-title-group><journal-title>International Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1201-9712</issn><issn pub-type="epub">1878-3511</issn><publisher><publisher-name>The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7470698</article-id><article-id pub-id-type="publisher-id">S1201-9712(20)30706-2</article-id><article-id pub-id-type="doi">10.1016/j.ijid.2020.08.076</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Nikolai</surname><given-names>Lea A.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Meyer</surname><given-names>Christian G.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Kremsner</surname><given-names>Peter G.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="aut0020"><name><surname>Velavan</surname><given-names>Thirumalaisamy P.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib><aff id="aff0005"><label>a</label>Institute of Tropical Medicine, University of T&#x000fc;bingen, T&#x000fc;bingen, Germany</aff><aff id="aff0010"><label>b</label>Vietnamese-German Center for Medical Research, Hanoi, Viet Nam</aff><aff id="aff0015"><label>c</label>Faculty of Medicine, Duy Tan University, Da Nang, Viet Nam</aff><aff id="aff0020"><label>d</label>Centre de Recherches Medicales de Lambarene, Gabon</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding author at: Institute of Tropical Medicine, University of T&#x000fc;bingen, Wilhelmstrasse 27, 72074 T&#x000fc;bingen, Germany.</corresp></author-notes><pub-date pub-type="pmc-release"><day>3</day><month>9</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>11</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>3</day><month>9</month><year>2020</year></pub-date><volume>100</volume><fpage>112</fpage><lpage>116</lpage><history><date date-type="received"><day>7</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>26</day><month>8</month><year>2020</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Author(s)</copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0005"><title>Highlights</title><p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>&#x02022;</label><p id="par0005">Characteristics of asymptomatic and presymptomatic infection are not identical.</p></list-item><list-item id="lsti0010"><label>&#x02022;</label><p id="par0010">Younger age correlates strongly with asymptomatic and mild infections.</p></list-item><list-item id="lsti0015"><label>&#x02022;</label><p id="par0015">Asymptomatic infections do not provide clear guidance for public-health measures.</p></list-item><list-item id="lsti0020"><label>&#x02022;</label><p id="par0020">Asymptomatic cases should be reported in official COVID-19 statistics.</p></list-item><list-item id="lsti0025"><label>&#x02022;</label><p id="par0025">Asymptomatic individuals carrying SARS-CoV-2 are hidden drivers of the pandemic.</p></list-item></list></p></abstract><abstract id="abs0010"><p>While successful containment measures of COVID-19 in China and many European countries have led to flattened curves, case numbers are rising dramatically in other countries, with the emergence of a second wave expected. Asymptomatic individuals carrying SARS-CoV-2 are hidden drivers of the pandemic, and infectivity studies confirm the existence of transmission by asymptomatic individuals. The data addressed here show that characteristics of asymptomatic and presymptomatic infection are not identical. Younger age correlates strongly with asymptomatic and mild infections and children as hidden drivers. The estimated proportion of asymptomatic infections ranges from 18% to 81%. The current perception of asymptomatic infections does not provide clear guidance for public-health measures. Asymptomatic infections will be a key contributor in the spread of COVID-19. Asymptomatic cases should be reported in official COVID-19 statistics.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>Asymptomatic</kwd><kwd>Presymptomatic</kwd><kwd>Case definition</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>Herd immunity</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><title>Introduction</title><p id="par0030">Transmission of SARS-CoV-2, the agent causing COVID-19, is driven by virus-containing droplets released from the upper airways and aerosols that can float, dependent on the airflow, for a prolonged period in the environment (<xref rid="bib0145" ref-type="bibr">Meselson, 2020</xref>). Aerosols can be spread by just breathing, while droplets originate from speaking, shouting, sneezing, and coughing as well as from singing and playing wind instruments (<xref rid="bib0290" ref-type="bibr">Zhang et al., 2020</xref>, <xref rid="bib0295" ref-type="bibr">Zhen-Dong et al., 2020</xref>, <xref rid="bib0015" ref-type="bibr">Asadi et al., 2019</xref>). Of great importance are super-spreading events, which are infection clusters constituting effective chains of SARS-CoV-2 transmission. For instance, such superspreading events have been observed in Hong Kong (<xref rid="bib0005" ref-type="bibr">Adam et al., 2020</xref>), at religious mass events in Iran (<xref rid="bib0155" ref-type="bibr">Mubarak and Zin, 2020</xref>) and choir rehearsals in the US (<xref rid="bib0070" ref-type="bibr">Hamner et al., 2020</xref>), where singing contributed to a maximum emission of droplets and aerosols and, thus, to successful transmission (<xref rid="bib0015" ref-type="bibr">Asadi et al., 2019</xref>).</p></sec><sec id="sec0010"><title>Defining &#x0201c;asymptomatic&#x0201d;</title><p id="par0035">Transmission of the virus by infected, albeit asymptomatic individuals has been reported since the early stages of the outbreak (<xref rid="bib0175" ref-type="bibr">Pan et al., 2020</xref>, <xref rid="bib0260" ref-type="bibr">Yan et al., 2020</xref>) posing substantial COVID-19 containment challenges. The likely spread of COVID-19 occurs to a large extent via asymptomatic individuals, as these do not present to health care or testing facilities. Uncertainty about the significance of asymptomatic infections is reinforced by the vagueness with which the term &#x0201c;asymptomatic&#x0201d; is used. WHO defines an asymptomatic case as a laboratory-confirmed infected person without overt symptoms (<xref rid="bib0255" ref-type="bibr">WHO, 2020</xref>). It remains to be established how thoroughly such a person needs to be examined clinically. Moreover, the distinction between asymptomatic and presymptomatic individuals is often neglected in COVID-19 case definitions.</p><p id="par0040">A distinction between asymptomatic and presymptomatic stages can currently only be made retrospectively, after the occurrence or non-occurrence of clinical symptoms. Recent evidence suggests that elevated serum/plasma lactate dehydrogenase levels may, already in the early stages, be indicative of presymptomatic infections and, thus, facilitate early differentiation (<xref rid="bib0170" ref-type="bibr">Ooi and Low, 2020</xref>). Diagnostic imaging cannot distinguish between the two infection stages, as, surprisingly, 30% of asymptomatic individuals showed ground-glass opacities, and 27% had diffuse consolidations (<xref rid="bib0130" ref-type="bibr">Long et al., 2020</xref>).</p></sec><sec id="sec0015"><title>Pandemic is driven by asymptomatic infections</title><p id="par0045">The frequency and infectivity of asymptomatically infected persons are the main reasons why COVID-19 has become a pandemic. Evidence has pointed to the need for strict tracking and testing of all contacts, regardless of apparent symptoms (<xref rid="bib0290" ref-type="bibr">Zhang et al., 2020</xref>, <xref rid="bib0170" ref-type="bibr">Ooi and Low, 2020</xref>, <xref rid="bib0025" ref-type="bibr">Baggett et al., 2020</xref>, <xref rid="bib0250" ref-type="bibr">Wei et al., 2020</xref>). However, detection of COVID-19 has long been driven by testing patients only, a practice still recommended in the EU/EEA (except Germany) and UK (<xref rid="bib0055" ref-type="bibr">European Centre for Disease Prevention and Control, 2020</xref>). Meanwhile, some countries have started to extend testing; Luxembourg and the state of Bavaria (Germany) have announced that the entire population of 600,000 and 13 million, respectively, shall be tested to prevent a second wave. The USA's Center for Disease Control (CDC) recommends diagnostic tests for both symptomatic and asymptomatic individuals with known or suspected exposure to COVID-19 (<xref rid="bib0195" ref-type="bibr">Prevention CfDCa, 2020a</xref>). At the same time, the European Centre for Disease Control (ECDC) proposes tests mainly for asymptomatic healthcare workers, when testing facilities are underutilized (<xref rid="bib0040" ref-type="bibr">Control ECfDPa, 2020</xref>).</p><p id="par0050">Since April 1, 2020, China has responded to the emerging significance of asymptomatic infections by establishing a separate category of "asymptomatic cases" in its daily COVID 19 statistics (<xref rid="bib0290" ref-type="bibr">Zhang et al., 2020</xref>). Mathematical modeling clearly supports broader test strategies. A simulation applying data from the Jiangsu Province, China, compared epidemiological data with an estimated asymptomatic proportion of 44% and found that asymptomatic individuals can cause faster and larger outbreaks than imported cases (<xref rid="bib0225" ref-type="bibr">Sun and Weng, 2020</xref>). Another analysis indicated that 30% of asymptomatic and 50% of symptomatic patients must be isolated to achieve disease control (<xref rid="bib0110" ref-type="bibr">Kassa et al., 2020</xref>).</p></sec><sec id="sec0020"><title>Asymptomatic infections during the pandemic</title><p id="par0055">Asymptomatic infections have increasingly been recognized in family clusters with unknown index cases. The first cluster study comprised five family members from Anyang, China, who developed COVID-19 symptoms and tested positive by RT-PCR after acquiring the infection from the index case, an asymptomatic visitor from Wuhan who later tested positive (<xref rid="bib0030" ref-type="bibr">Bai et al., 2020</xref>). Another study with five family members from Luzhou, China, described a patient who developed severe COVID-19 pneumonia after attending a family reunion. Apparently, he had acquired COVID-19 from an asymptomatic relative from Wuhan (<xref rid="bib0270" ref-type="bibr">Ye et al., 2020</xref>).</p><p id="par0060">Several studies have focused on determining the incidence of asymptomatic infections. On the cruise ship Diamond Princess, with 3711 passengers, a major outbreak of 634 cases occurred after an infected asymptomatic passenger had boarded in Hong Kong. Due to the dense living conditions and frequent passenger contacts, the R0 value was initially four times higher than in Wuhan (<xref rid="bib0205" ref-type="bibr">Rockl&#x000f6;v et al., 2020</xref>). The true asymptomatic proportion, defined as those who never developed symptoms, among all infected passengers was 18% (<xref rid="bib0150" ref-type="bibr">Mizumoto et al., 2020</xref>). Similar to the Diamond Princess, another study of an Argentinian expedition cruise ship found that 59% of the 217 passengers tested positive for COVID-19; 81% of those infected were asymptomatic virus carriers (<xref rid="bib0090" ref-type="bibr">Ing et al., 2020</xref>). In Vo, the first Italian city with a confirmed COVID-19 fatality, 3711 were surveyed twice. 2.6 % of the population tested positive before the lockdown, and 1.2 % tested positive after the lockdown; of these, 41% and 45% were asymptomatic before and after the lockdown, respectively (<xref rid="bib0125" ref-type="bibr">Lavezzo et al., 2020</xref>). When screening individuals in Gangelt, Germany, 22% of individuals positive for COVID-19 remained asymptomatic (<xref rid="bib0220" ref-type="bibr">Streeck et al., 2020</xref>). In another study of individuals repatriated from Wuhan to Japan, 13 of the 565 (2%) evacuated tested positive, and 31% of those evacuated remained asymptomatic after a sufficiently long time to complete the incubation period (<xref rid="bib0160" ref-type="bibr">Nishiura et al., 2020</xref>). A first nationwide population-based study from Spain, including 61,000 participants from 35,883 households, concluded that one in three infections seems to be asymptomatic and emphasized the need to maintain public health measures to avoid a second epidemic wave (<xref rid="bib0185" ref-type="bibr">Poll&#x000e1;n et al., 2020</xref>).</p><p id="par0065">As these findings differ significantly, it is difficult to accurately determine the extent of asymptomatic infections. Discrepancies could result from imprecise definitions of the term &#x0201c;asymptomatic&#x0201d; or a different understanding of &#x0201c;asymptomatic&#x0201d; in the various studies (<xref rid="tbl0005" ref-type="table">Table1</xref>
). Extremely high incidences could result from the unintended inclusion of presymptomatic and very mild cases. The true incidence of asymptomatic infections can only be determined if close surveillance is initiated and continued at least over the estimated average incubation period of at least five days in order not to miss a possible onset of symptoms.<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Limited overview of reported studies on asymptomatic infection among adults and children.</p></caption><alt-text id="at0015">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Reported studies</th><th align="left">Sample size</th><th align="left">Country</th><th align="left">Estimates</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Passenger ship: Diamond Princess</td><td align="left">n = 3711</td><td align="left">Yokohama, Japan</td><td align="left">18%</td><td align="left"><xref rid="bib0205" ref-type="bibr">Rockl&#x000f6;v et al. (2020</xref>); <xref rid="bib0150" ref-type="bibr">Mizumoto et al. (2020</xref>)</td></tr><tr><td align="left">Argentinian expedition cruise ship</td><td align="left">n = 217</td><td align="left">Montevideo, Uruguay</td><td align="left">81%</td><td align="left"><xref rid="bib0090" ref-type="bibr">Ing et al. (2020</xref>)</td></tr><tr><td align="left">Two-point prevalence survey</td><td align="left">n = 2343</td><td align="left">Vo, Padua, Italy</td><td align="left">41% and 45%</td><td align="left"><xref rid="bib0125" ref-type="bibr">Lavezzo et al. (2020</xref>)</td></tr><tr><td align="left">Sero-epidemiological study</td><td align="left">n = 919</td><td align="left">Gangelt, Germany</td><td align="left">22%</td><td align="left"><xref rid="bib0220" ref-type="bibr">Streeck et al. (2020</xref>)</td></tr><tr><td align="left">Repatriated passengers</td><td align="left">n = 565</td><td align="left">Japan</td><td align="left">31%</td><td align="left"><xref rid="bib0160" ref-type="bibr">Nishiura et al. (2020</xref>)</td></tr><tr><td align="left">Nationwide population-based study</td><td align="left">n = 61,000</td><td align="left">Spain</td><td align="left">22 to 36%</td><td align="left"><xref rid="bib0185" ref-type="bibr">Poll&#x000e1;n et al. (2020</xref>)</td></tr><tr><td align="left">Presymptomatic surveillance study</td><td align="left">n = 243</td><td align="left">Singapore</td><td align="left">6%</td><td align="left"><xref rid="bib0250" ref-type="bibr">Wei et al. (2020</xref>)</td></tr><tr><td align="left">Followed up case series</td><td align="left">n = 78</td><td align="left">Wuhan, China</td><td align="left">42%</td><td align="left"><xref rid="bib0265" ref-type="bibr">Yang et al. (2020</xref>)</td></tr><tr><td align="left">Viral dynamics: Asymptomatic patients</td><td align="left">n = 31</td><td align="left">Guangzhou, China</td><td align="left">29%</td><td align="left"><xref rid="bib0300" ref-type="bibr">Zhou et al. (2020</xref>)</td></tr><tr><td align="left">Nationwide case series: Children</td><td align="left">n = 2135</td><td align="left">China</td><td align="left">4%</td><td align="left"><xref rid="bib0045" ref-type="bibr">Dong et al. (2020</xref>)</td></tr></tbody></table></table-wrap></p></sec><sec id="sec0025"><title>Asymptomatic infectivity: viral load and viral shedding</title><p id="par0070">When assessing public health risks raised by asymptomatic COVID-19 cases, it is important to determine whether the infectivity varies between asymptomatic, presymptomatic, and symptomatic individuals. A study of the first 243 patients in Singapore revealed a proportion of 6% presymptomatic cases with transmission occurring 1&#x02013;3 days before the onset of symptoms (<xref rid="bib0250" ref-type="bibr">Wei et al., 2020</xref>). Data from three Chinese hospitals, including 24 asymptomatic subjects, showed an average SARS-CoV-2 carrier period of 22 days. The time from exposure to eventual negativity indicates that asymptomatically infected persons likely carry the virus for a relatively long period (<xref rid="bib0260" ref-type="bibr">Yan et al., 2020</xref>). Infectivity exists in presymptomatic and/or asymptomatic men; however, further analyses of the viral loads and viral shedding duration are required. Viral shedding is the release of the virus from somatic cells after replication; it does not necessarily imply that it is infectious (<xref rid="bib0020" ref-type="bibr">Atkinson and Petersen, 2020</xref>). The virus load is measured by the cycle threshold (Ct value), which corresponds to the diagnostic RT-PCR assays' amplification cycles. Ct values increase with decreasing viral load; low Ct values indicate a high viral load. Also, the duration of virus detectability serves as an indicator of infectivity.</p><p id="par0075">In a study of 21 infected Chinese, a subgroup of five asymptomatic patients had the longest period of RNA positivity, with prolonged viral shedding. The virus was thriving in asymptomatic subjects for a median of 18 days compared to mild (median 10 days) and severe COVID-19 cases (median 14 days) (<xref rid="bib0275" ref-type="bibr">Yongchen et al., 2020</xref>). Another study from Wanzhou district, China, compared 37 asymptomatic with 37 symptomatic individuals. Although the initial Ct values were similar, asymptomatic individuals showed prolonged virus release (asymptomatic individuals: median 19 days, symptomatic individuals 14 days) (<xref rid="bib0130" ref-type="bibr">Long et al., 2020</xref>). Of interest is also another study of 18 patients from Zhuhai, China, where viral loads in asymptomatics were similar to those in patients (<xref rid="bib0310" ref-type="bibr">Zou et al., 2020</xref>). In the Vo community study in Italy, no significant differences were found between viral loads of asymptomatic and presymptomatic individuals, and no differences in the duration of virus detectability were seen (<xref rid="bib0125" ref-type="bibr">Lavezzo et al., 2020</xref>).</p><p id="par0080">Data of 78 infected subjects from Wuhan identified 33 (42%) asymptomatic infections with shorter periods of viral shedding compared to symptomatic patients (eight vs.19 days) (<xref rid="bib0265" ref-type="bibr">Yang et al., 2020</xref>). A cohort of 71 South Koreans included three presymptomatic and ten asymptomatic subjects. Asymptomatics had lower Ct values than presymptomatic subjects over a period of 15 days, indicating a higher viral load (<xref rid="bib0115" ref-type="bibr">Kim et al., 2020</xref>). Of 31 infected persons from Guangzhou, China, who tested positive, 22 proved to be presymptomatic on admission and developed symptoms later, whereas nine remained asymptomatic. There was a statistically significant difference between asymptomatic and presymptomatic infection, with higher Ct values in asymptomatic than in presymptomatic individuals. However, there was no significant difference in viral shedding (<xref rid="bib0300" ref-type="bibr">Zhou et al., 2020</xref>). Also, infectivity was found to be highest roughly a day before symptom onset; it was estimated that 44% of secondary cases were infected by a presymptomatic carrier (<xref rid="bib0075" ref-type="bibr">He et al., 2020</xref>).</p><p id="par0085">To ascertain an asymptomatic who does not meet the case definition, the detection of SARS-CoV-2 by RT-PCR on nasopharyngeal and oropharyngeal swabs is the only currently available standard diagnosis (<xref rid="bib0280" ref-type="bibr">Younes et al., 2020</xref>). Recent studies raise the question of the reliability of RT-PCR based on increasing evidence of false-negative cases and concerns about its applicability (<xref rid="bib0010" ref-type="bibr">Arevalo-Rodriguez et al., 2020</xref>, <xref rid="bib0180" ref-type="bibr">Piras et al., 2020</xref>). False-negative results can have a significant negative impact on efforts to contain the epidemic. The probability of false-negative results in RT-PCR tests is influenced by the time since exposure and the onset of symptoms (<xref rid="bib0120" ref-type="bibr">Kucirka et al., 2020</xref>). On the other hand, technical problems, insufficient virus load, and inadequate and inappropriate sampling may be other reasonable causes of false-negative results. The challenges in laboratory diagnosis of SARS-CoV-2 by RT-PCR are multifactorial, and well-defined guidelines are warranted to fill the gaps in the detection of SARS-CoV-2 in asymptomatics.</p></sec><sec id="sec0030"><title>Age stratified asymptomatic infection</title><p id="par0090">When analyzing common characteristics of patients, young age often correlated with asymptomatic or mild manifestations of COVID-19. Among 78 patients from Wuhan, China, asymptomatic individuals were younger than symptomatic patients (median age 37 vs. 56 years) (<xref rid="bib0265" ref-type="bibr">Yang et al., 2020</xref>). In Nanjing, China, of 24 initially asymptomatic subjects, 29% who never showed symptoms were significantly younger than the presymptomatic group (<xref rid="bib0085" ref-type="bibr">Hu et al., 2020</xref>). These results are supported by the data from the cruise ship, Diamond Princess; of 96 asymptomatic persons, eleven later developed symptoms that made them presymptomatic. The probability of evolving to a presymptomatic stage increased with age (<xref rid="bib0210" ref-type="bibr">Sakurai et al., 2020</xref>).</p><p id="par0095">In fact, a much lower prevalence of COVID-19 is observed in children than in adults, with people under 18 years accounting for only 5% of cases in the USA compared to 22% in the total population (<xref rid="bib0200" ref-type="bibr">Prevention CfDCa, 2020b</xref>). Of 1412 Chinese children with infection, 4% and 51% were categorized as asymptomatic and mild, respectively (<xref rid="bib0045" ref-type="bibr">Dong et al., 2020</xref>).</p><p id="par0100">Recent evidence suggests that the entry of SARS-CoV-2 via the ACE2 receptor is facilitated by the membrane-bound serine protease TMPRSS2, which primes the viral S protein for fusogenic activity (<xref rid="bib0080" ref-type="bibr">Hoffmann et al., 2020</xref>, <xref rid="bib0285" ref-type="bibr">Zang et al., 2020</xref>). Since <italic>TMPRSS2</italic> is a gene associated with androgen levels, a higher expression occurs in males, which provides one explanation of why they are more likely to develop severe COVID-19 (<xref rid="bib0035" ref-type="bibr">Bhowmick et al., 2020</xref>). This association also applies to the distinction between preadolescents and adults and is in line with low incidences and relatively mild disease courses in children (<xref rid="bib0240" ref-type="bibr">Wambier et al., 2020</xref>). Since this also indicates a higher incidence of asymptomatic infections in younger people, it needs to be examined whether this group, especially children, could silently, yet efficiently, contribute to the spread of COVID-19.</p><p id="par0105">In Geneva, Switzerland, 79% of all RT-PCR-positive children under 16 years of age were infected in household clusters (<xref rid="bib0190" ref-type="bibr">Posfay-Barbe et al., 2020</xref>), and in Wuhan, China, as many as 90% of this group were infected by a family member (<xref rid="bib0135" ref-type="bibr">Lu et al., 2020</xref>). A systematic review identified 31 household clusters, of which only 10% had pediatric index cases compared to 54% in H5N1 influenza (<xref rid="bib0305" ref-type="bibr">Zhu et al., 2020</xref>). Together with evidence of lower viral loads and milder respiratory symptoms in children, these observations have led to the conclusion that children are unlikely to be the leading cause of the pandemic (<xref rid="bib0140" ref-type="bibr">Ludvigsson, 2020</xref>). Consequently, the re-opening of kindergartens and schools has been proposed. A low attack rate among children may yet be biased because the risk of infection is lowest for children (<xref rid="bib0060" ref-type="bibr">Garc&#x000ed;a-Salido, 2020</xref>). Current data from Berlin, Germany, did not show significant differences in viral loads between age groups, suggesting that children may be as infectious as adults (<xref rid="bib0100" ref-type="bibr">Jones et al., 2020</xref>).</p><p id="par0110">Neglecting the role of children in the spread of COVID-19 is precarious. It is important in modeling the pandemic to undertake careful surveillance, including asymptomatic children with rates of infections assessed by serology, to better characterize childhood infection and the role of children in transmission networks (<xref rid="bib0235" ref-type="bibr">Velavan et al., 2020</xref>). Children need protection, as some become ill, although severely ill only in a minority of cases. COVID-19 vaccination of children may provide protection for older, unvaccinated populations. Vaccination of children will lead to a great deal of immunity required for overall protection in any population (<xref rid="bib0235" ref-type="bibr">Velavan et al., 2020</xref>, <xref rid="bib0105" ref-type="bibr">Kao et al., 2020</xref>).</p></sec><sec id="sec0035"><title>Asymptomatic infection: hope for herd immunity</title><p id="par0115">Studies suggesting high incidences of transmission through asymptomatic individuals have raised hope that comprehensive immunization of the population may occur unnoticed. In general, about two-thirds of a population must be immunized to achieve herd immunity. On June 24, 2020, the countries with the highest incidences of COVID-19 were the USA, Brazil, Russia, India, and the United Kingdom, with case numbers representing 0.71%, 0.54%, 0.43%, 0.03%, and 0.47% of the population, respectively; these percentages are far from herd immunity (<xref rid="bib0095" ref-type="bibr">Johns Hopkins University and Medicine, 2020</xref>).</p><p id="par0120">In Gangelt (Germany), an event linked to carnival celebrations caused SARS-CoV-2 to spread throughout the city, resulting in 3% of the population with positive RT-PCR results. Serological screening revealed later that 16% of the population were exposed (<xref rid="bib0220" ref-type="bibr">Streeck et al., 2020</xref>). Even in densely populated and severely affected areas, the prevalence of anti-SARS-CoV-2 antibodies is still relatively low, e.g., 11% in Madrid, Spain (<xref rid="bib0065" ref-type="bibr">Gobierno de Espa&#x000f1;a MdCeI et al., 2020</xref>), 15% in London, UK (<xref rid="bib0050" ref-type="bibr">England, 2020</xref>), and 20% in New York City, USA (<xref rid="bib0215" ref-type="bibr">State of NY, 2020</xref>).</p><p id="par0125">It is still unclear whether asymptomatic infections lead to protective immunity. It was observed that, although all patients with severe and mild COVID-19 experienced seroconversion during or after hospitalization, only one in five asymptomatic patients seroconverted (<xref rid="bib0275" ref-type="bibr">Yongchen et al., 2020</xref>). Another comparison between an asymptomatic and a symptomatic cohort showed that IgG levels were significantly higher in the symptomatic group (<xref rid="bib0130" ref-type="bibr">Long et al., 2020</xref>). However, data from two hospitals in Hong Kong suggest that the disease's severity is not correlated with serum antibody levels (<xref rid="bib0230" ref-type="bibr">To et al., 2020</xref>). It would not only be misleading but dangerous to rely on silent immunization. Apparently, so far, only a small proportion of the population has been exposed to SARS-CoV-2.</p></sec><sec id="sec0040"><title>Public health implications</title><p id="par0130">The current perception of asymptomatic infections does not provide clear guidance for public health measures. As asymptomatic and presymptomatic infections are not distinguishable at first sight, they may pose a significant threat to public health during the unlocking of lockdown strategies currently being implemented in many countries.</p><p id="par0135">Therefore, public health measures need to further include&#x02013;mandatorily and for an unforeseeable period&#x02013;proper hygiene measures and personal protective equipment to prevent spread by asymptomatic individuals. All contacts of infected persons must test for COVID-19, regardless of symptoms. Asymptomatic cases should be reported separately in official COVID-19 statistics, and shifts from asymptomatic to symptomatic stages must be reported to health authorities. Mass rallies and major events continue to need to be postponed or canceled.</p></sec><sec id="sec0045"><title>Conclusions</title><p id="par0140">Asymptomatic infections are an important aspect of SARS-CoV-2 infection, and the data addressed here show that the characteristics of asymptomatic and presymptomatic infection are not identical. Asymptomatic infections will be a key contributor to COVID-19 spread. Infectivity studies confirm the existence of transmission by asymptomatic individuals but are contradictory when comparing viral loads and virus shedding in symptomatic and asymptomatic infections. Younger age correlates strongly with asymptomatic and mild infections and consequently suggests children as hidden drivers of the pandemic. However, since childhood infections are usually far below the age average in COVID-19 infections, children's role in transmission events is not yet clear.</p><p id="par0145">While public health measures might be practical in wealthy countries with well-established and relatively stable health care systems, the question of how the pandemic will affect low- and middle-income countries, as observed in South America or on the African continent, still remains unanswered (<xref rid="bib0165" ref-type="bibr">Ntoumi and Velavan, 2020</xref>, <xref rid="bib0245" ref-type="bibr">Wang et al., 2020</xref>). The international community is obliged to pay attention to the spread of COVID-19 in low-income countries, as health systems could become severely overburdened, and the pandemic could continue to elude control, hitting hardest those with the least protection.</p></sec><sec id="sec0050"><title>Conflict of interest</title><p id="par0150">All authors disclose no conflict of interest.</p></sec><sec id="sec0055"><title>Funding source</title><p id="par0155">The authors acknowledge the <funding-source id="gs0005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002347</institution-id><institution>Federal Ministry of Education and Research</institution></institution-wrap></funding-source> (BMBF) (BMBF-01KI2052) and the <funding-source id="gs0010"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003107</institution-id><institution>Federal Ministry of Health</institution></institution-wrap></funding-source> (BMG) (BMG-ZMVI1-1520COR801).</p></sec><sec id="sec0060"><title>Ethical approval</title><p id="par0160">Not applicable.</p></sec><sec id="sec0065"><title>Contribution statement</title><p id="par0165">All authors have an academic interest and contributed equally. The authors TPV and LAN conducted the literature search, collected data, collated all information, and wrote the review. The authors CGM and PGK contributed to the study design and revised the review draft. TPV is a member of the Pan African Network for Rapid Research, Response, and Preparedness for Infectious Diseases Epidemics consortium (PANDORA-ID-NET RIA2016E-1609).</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>D.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Wong</surname><given-names>J.</given-names></name><name><surname>Lau</surname><given-names>E.</given-names></name><name><surname>Tsang</surname><given-names>T.</given-names></name><name><surname>Cauchemez</surname><given-names>S.</given-names></name></person-group><article-title>Clustering and superspreading potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Hong Kong</article-title><source>Res Square</source><year>2020</year><pub-id pub-id-type="doi">10.21203/rs.3.rs-29548/v1</pub-id></element-citation></ref><ref id="bib0010"><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Arevalo-Rodriguez</surname><given-names>I.</given-names></name><name><surname>Buitrago-Garcia</surname><given-names>D.</given-names></name><name><surname>Simancas-Racines</surname><given-names>D.</given-names></name><name><surname>Zambrano-Achig</surname><given-names>P.</given-names></name><name><surname>del Campo</surname><given-names>R.</given-names></name><name><surname>Ciapponi</surname><given-names>A.</given-names></name></person-group><article-title>False-negative results of initial RT-PCR assays for COVID-19: a systematic review</article-title><source>medRxiv</source><year>2020</year><comment>2020.2004.2016.20066787</comment></element-citation></ref><ref id="bib0015"><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Asadi</surname><given-names>S.</given-names></name><name><surname>Wexler</surname><given-names>A.S.</given-names></name><name><surname>Cappa</surname><given-names>C.D.</given-names></name><name><surname>Barreda</surname><given-names>S.</given-names></name><name><surname>Bouvier</surname><given-names>N.M.</given-names></name><name><surname>Ristenpart</surname><given-names>W.D.</given-names></name></person-group><article-title>Aerosol emission and superemission during human speech increase with voice loudness</article-title><source>Sci Rep</source><volume>9</volume><issue>1</issue><year>2019</year><fpage>2348</fpage><pub-id pub-id-type="pmid">30787335</pub-id></element-citation></ref><ref id="bib0020"><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>B.</given-names></name><name><surname>Petersen</surname><given-names>E.</given-names></name></person-group><article-title>SARS-CoV-2 shedding and infectivity</article-title><source>Lancet</source><volume>395</volume><issue>10233</issue><year>2020</year><fpage>1339</fpage><lpage>1340</lpage></element-citation></ref><ref id="bib0025"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Baggett</surname><given-names>T.P.</given-names></name><name><surname>Keyes</surname><given-names>H.</given-names></name><name><surname>Sporn</surname><given-names>N.</given-names></name><name><surname>Gaeta</surname><given-names>J.M.</given-names></name></person-group><article-title>COVID-19 outbreak at a large homeless shelter in Boston: implications for universal testing</article-title><source>medRxiv</source><year>2020</year><comment>2020.2004.2012.20059618</comment></element-citation></ref><ref id="bib0030"><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>T.</given-names></name><name><surname>Tian</surname><given-names>F.</given-names></name><name><surname>Jin</surname><given-names>D.Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Presumed asymptomatic carrier transmission of COVID-19</article-title><source>JAMA</source><volume>323</volume><issue>14</issue><year>2020</year><fpage>1406</fpage><lpage>1407</lpage><pub-id pub-id-type="pmid">32083643</pub-id></element-citation></ref><ref id="bib0035"><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Bhowmick</surname><given-names>N.A.</given-names></name><name><surname>Oft</surname><given-names>J.</given-names></name><name><surname>Dorff</surname><given-names>T.</given-names></name><name><surname>Pal</surname><given-names>S.</given-names></name><name><surname>Agarwal</surname><given-names>N.</given-names></name><name><surname>Figlin</surname><given-names>R.A.</given-names></name></person-group><article-title>COVID-19 and androgen targeted therapy for prostate cancer patients</article-title><source>Endocr Relat Cancer</source><volume>27</volume><issue>9</issue><year>2020</year><fpage>R281</fpage><lpage>R292</lpage><pub-id pub-id-type="pmid">32508311</pub-id></element-citation></ref><ref id="bib0040"><mixed-citation publication-type="other" id="oref0040">Control ECfDPa. Testing strategies 2020 [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/covid-19/surveillance/testing-strategies" id="intr0005">https://www.ecdc.europa.eu/en/covid-19/surveillance/testing-strategies</ext-link>.</mixed-citation></ref><ref id="bib0045"><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Mo</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>F.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name></person-group><article-title>Epidemiology of COVID-19 among children in China</article-title><source>Pediatrics</source><volume>145</volume><issue>6</issue><year>2020</year></element-citation></ref><ref id="bib0050"><element-citation publication-type="book" id="sbref0050"><person-group person-group-type="author"><name><surname>England</surname><given-names>P.H.</given-names></name></person-group><chapter-title>Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report Summary of COVID-19 surveillance systems</chapter-title><year>2020</year><comment>[Available from: <ext-link ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/888254/COVID19_Epidemiological_Summary_w22_Final.pdf" id="intr0010">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/888254/COVID19_Epidemiological_Summary_w22_Final.pdf</ext-link></comment></element-citation></ref><ref id="bib0055"><element-citation publication-type="book" id="sbref0055"><person-group person-group-type="author"><name><surname>European Centre for Disease Prevention and Control</surname></name></person-group><chapter-title>Strategies for the Surveillance of COVID-19. Stockholm: ECDC; 2020</chapter-title><year>2020</year><publisher-name>European Centre for Disease Prevention and Control</publisher-name><comment>09.April</comment></element-citation></ref><ref id="bib0060"><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Salido</surname><given-names>A.</given-names></name></person-group><article-title>SARS-COV-2 children transmission: the evidence is that today we do not have enough evidence</article-title><source>Acta Paediatr</source><volume>109</volume><issue>9</issue><year>2020</year><fpage>1912</fpage><pub-id pub-id-type="pmid">32506837</pub-id></element-citation></ref><ref id="bib0065"><mixed-citation publication-type="other" id="oref0065">Gobierno de Espa&#x000f1;a MdCeI, Ministerio de Sanidad, Instituto de Salud Carlos III, Consejo Interterritorial. Estudio ENE-Covid19: Primera Ronda Estudio Nacional de sero-Epidemiolog&#x000ed;a de la infecci&#x000f3;n por SARS-CoV-2 en Espa&#x000f1;a (ENE-Covid19) Informe Preliminar 13 de Mayo de 2020. 2020 [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.lamoncloa.gob.es/serviciosdeprensa/notasprensa/sanidad14/Documents/2020/130520-ENE-COVID_Informe1.pdf" id="intr0015">https://www.lamoncloa.gob.es/serviciosdeprensa/notasprensa/sanidad14/Documents/2020/130520-ENE-COVID_Informe1.pdf</ext-link>.</mixed-citation></ref><ref id="bib0070"><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Hamner</surname><given-names>L.</given-names></name><name><surname>Dubbel</surname><given-names>P.</given-names></name><name><surname>Capron</surname><given-names>I.</given-names></name><name><surname>Ross</surname><given-names>A.</given-names></name><name><surname>Jordan</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name></person-group><article-title>High SARS-CoV-2 attack rate following exposure at a choir practice - Skagit County, Washington, March 2020</article-title><source>MMWR Morb Mortal Wkly Rep</source><volume>69</volume><issue>19</issue><year>2020</year><fpage>606</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">32407303</pub-id></element-citation></ref><ref id="bib0075"><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Lau</surname><given-names>E.H.Y.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Hao</surname><given-names>X.</given-names></name></person-group><article-title>Temporal dynamics in viral shedding and transmissibility of COVID-19</article-title><source>Nat Med</source><volume>26</volume><issue>5</issue><year>2020</year><fpage>672</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">32296168</pub-id></element-citation></ref><ref id="bib0080"><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><issue>2</issue><year>2020</year><comment>271-280.e278</comment></element-citation></ref><ref id="bib0085"><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Jin</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name></person-group><article-title>Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China</article-title><source>Sci China Life Sci</source><volume>63</volume><issue>5</issue><year>2020</year><fpage>706</fpage><lpage>711</lpage><pub-id pub-id-type="pmid">32146694</pub-id></element-citation></ref><ref id="bib0090"><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Ing</surname><given-names>A.J.</given-names></name><name><surname>Cocks</surname><given-names>C.</given-names></name><name><surname>Green</surname><given-names>J.P.</given-names></name></person-group><article-title>COVID-19: in the footsteps of Ernest Shackleton</article-title><source>Thorax</source><volume>75</volume><issue>8</issue><year>2020</year><fpage>693</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">32461231</pub-id></element-citation></ref><ref id="bib0095"><mixed-citation publication-type="other" id="oref0095">Johns Hopkins University &#x00026; Medicine. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) 2020 [Available from: <ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html" id="intr0020">https://coronavirus.jhu.edu/map.html</ext-link>.</mixed-citation></ref><ref id="bib0100"><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>T.C.</given-names></name><name><surname>M&#x000fc;hlemann</surname><given-names>B.</given-names></name><name><surname>Veith</surname><given-names>T.</given-names></name><name><surname>Biele</surname><given-names>G.</given-names></name><name><surname>Zuchowski</surname><given-names>M.</given-names></name><name><surname>Hoffmann</surname><given-names>J.</given-names></name></person-group><article-title>An analysis of SARS-CoV-2 viral load by patient age</article-title><source>medRxiv</source><year>2020</year><comment>2020.2006.2008.20125484</comment></element-citation></ref><ref id="bib0105"><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>C.M.</given-names></name><name><surname>Orenstein</surname><given-names>W.A.</given-names></name><name><surname>Anderson</surname><given-names>E.J.</given-names></name></person-group><article-title>The importance of advancing SARS-CoV-2 vaccines in children</article-title><source>Clin Infect Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa712</pub-id></element-citation></ref><ref id="bib0110"><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Kassa</surname><given-names>S.M.</given-names></name><name><surname>Njagarah</surname><given-names>J.B.H.</given-names></name><name><surname>Terefe</surname><given-names>Y.A.</given-names></name></person-group><article-title>Analysis of the mitigation strategies for COVID-19: from mathematical modelling perspective</article-title><source>Chaos Solitons Fractals</source><volume>138</volume><year>2020</year><fpage>109968</fpage><pub-id pub-id-type="pmid">32536760</pub-id></element-citation></ref><ref id="bib0115"><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.E.</given-names></name><name><surname>Jeong</surname><given-names>H.S.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Shin</surname><given-names>S.U.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Oh</surname><given-names>T.H.</given-names></name></person-group><article-title>Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients</article-title><source>Int J Infect Dis</source><volume>95</volume><year>2020</year><fpage>441</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">32376309</pub-id></element-citation></ref><ref id="bib0120"><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Kucirka</surname><given-names>L.M.</given-names></name><name><surname>Lauer</surname><given-names>S.A.</given-names></name><name><surname>Laeyendecker</surname><given-names>O.</given-names></name><name><surname>Boon</surname><given-names>D.</given-names></name><name><surname>Lessler</surname><given-names>J.</given-names></name></person-group><article-title>Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure</article-title><source>Ann Intern Med</source><volume>173</volume><issue>4</issue><year>2020</year><fpage>262</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">32422057</pub-id></element-citation></ref><ref id="bib0125"><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Lavezzo</surname><given-names>E.</given-names></name><name><surname>Franchin</surname><given-names>E.</given-names></name><name><surname>Ciavarella</surname><given-names>C.</given-names></name><name><surname>Cuomo-Dannenburg</surname><given-names>G.</given-names></name><name><surname>Barzon</surname><given-names>L.</given-names></name><name><surname>Del Vecchio</surname><given-names>C.</given-names></name></person-group><article-title>Suppression of COVID-19 outbreak in the municipality of Vo, Italy</article-title><source>medRxiv</source><year>2020</year><comment>2020.2004.2017.20053157</comment></element-citation></ref><ref id="bib0130"><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Long</surname><given-names>Q.X.</given-names></name><name><surname>Tang</surname><given-names>X.J.</given-names></name><name><surname>Shi</surname><given-names>Q.L.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Deng</surname><given-names>H.J.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name></person-group><article-title>Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections</article-title><source>Nat Med</source><volume>26</volume><year>2020</year><fpage>1200</fpage><lpage>1204</lpage><pub-id pub-id-type="pmid">32555424</pub-id></element-citation></ref><ref id="bib0135"><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Du</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.Y.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name></person-group><article-title>SARS-CoV-2 infection in children</article-title><source>N Engl J Med</source><volume>382</volume><issue>17</issue><year>2020</year><fpage>1663</fpage><lpage>1665</lpage><pub-id pub-id-type="pmid">32187458</pub-id></element-citation></ref><ref id="bib0140"><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Ludvigsson</surname><given-names>J.F.</given-names></name></person-group><article-title>Children are unlikely to be the main drivers of the COVID-19 pandemic&#x02013;a systematic review</article-title><source>Acta Paediatr</source><volume>109</volume><issue>8</issue><year>2020</year><fpage>1525</fpage><lpage>1530</lpage><pub-id pub-id-type="pmid">32430964</pub-id></element-citation></ref><ref id="bib0145"><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Meselson</surname><given-names>M.</given-names></name></person-group><article-title>Droplets and aerosols in the transmission of SARS-CoV-2</article-title><source>N Engl J Med</source><volume>382</volume><issue>21</issue><year>2020</year><fpage>2063</fpage><pub-id pub-id-type="pmid">32294374</pub-id></element-citation></ref><ref id="bib0150"><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Mizumoto</surname><given-names>K.</given-names></name><name><surname>Kagaya</surname><given-names>K.</given-names></name><name><surname>Zarebski</surname><given-names>A.</given-names></name><name><surname>Chowell</surname><given-names>G.</given-names></name></person-group><article-title>Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020</article-title><source>Euro Surveill</source><volume>25</volume><issue>10</issue><year>2020</year></element-citation></ref><ref id="bib0155"><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Mubarak</surname><given-names>N.</given-names></name><name><surname>Zin</surname><given-names>C.S.</given-names></name></person-group><article-title>Religious tourism and mass religious gatherings-the potential link in the spread of COVID-19. Current perspective and future implications</article-title><source>Travel Med Infect Dis</source><volume>36</volume><year>2020</year><fpage>101786</fpage><pub-id pub-id-type="pmid">32531422</pub-id></element-citation></ref><ref id="bib0160"><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Nishiura</surname><given-names>H.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Miyama</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>A.</given-names></name><name><surname>Jung</surname><given-names>S.M.</given-names></name><name><surname>Hayashi</surname><given-names>K.</given-names></name></person-group><article-title>Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)</article-title><source>Int J Infect Dis</source><volume>94</volume><year>2020</year><fpage>154</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">32179137</pub-id></element-citation></ref><ref id="bib0165"><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Ntoumi</surname><given-names>F.</given-names></name><name><surname>Velavan</surname><given-names>T.P.</given-names></name></person-group><article-title>COVID-19 in Africa: between hope and reality</article-title><source>Lancet Infect Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30465-5</pub-id></element-citation></ref><ref id="bib0170"><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>E.E.</given-names></name><name><surname>Low</surname><given-names>J.G.</given-names></name></person-group><article-title>Asymptomatic SARS-CoV-2 infection</article-title><source>Lancet Infect Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30460-6</pub-id></element-citation></ref><ref id="bib0175"><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Ou</surname><given-names>X.</given-names></name></person-group><article-title>Asymptomatic cases in a family cluster with SARS-CoV-2 infection</article-title><source>Lancet Infect Dis</source><volume>20</volume><issue>4</issue><year>2020</year><fpage>410</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">32087116</pub-id></element-citation></ref><ref id="bib0180"><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Piras</surname><given-names>A.</given-names></name><name><surname>Rizzo</surname><given-names>D.</given-names></name><name><surname>Uzzau</surname><given-names>S.</given-names></name><name><surname>De Riu</surname><given-names>G.</given-names></name><name><surname>Rubino</surname><given-names>S.</given-names></name><name><surname>Bussu</surname><given-names>F.</given-names></name></person-group><article-title>Inappropriate nasopharyngeal sampling for SARS-CoV-2 detection is a relevant cause of false-negative reports</article-title><source>Otolaryngol Head Neck Surg</source><year>2020</year><comment>194599820931793</comment></element-citation></ref><ref id="bib0185"><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Poll&#x000e1;n</surname><given-names>M.</given-names></name><name><surname>P&#x000e9;rez-G&#x000f3;mez</surname><given-names>B.</given-names></name><name><surname>Pastor-Barriuso</surname><given-names>R.</given-names></name><name><surname>Oteo</surname><given-names>J.</given-names></name><name><surname>Hern&#x000e1;n</surname><given-names>M.A.</given-names></name><name><surname>P&#x000e9;rez-Olmeda</surname><given-names>M.</given-names></name></person-group><article-title>Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study</article-title><source>Lancet</source><volume>396</volume><issue>10250</issue><year>2020</year><fpage>535</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">32645347</pub-id></element-citation></ref><ref id="bib0190"><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Posfay-Barbe</surname><given-names>K.M.</given-names></name><name><surname>Wagner</surname><given-names>N.</given-names></name><name><surname>Gauthey</surname><given-names>M.</given-names></name><name><surname>Moussaoui</surname><given-names>D.</given-names></name><name><surname>Loevy</surname><given-names>N.</given-names></name><name><surname>Diana</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 in children and the dynamics of infection in families</article-title><source>Pediatrics</source><volume>146</volume><issue>2</issue><year>2020</year><object-id pub-id-type="publisher-id">e20201576</object-id></element-citation></ref><ref id="bib0195"><mixed-citation publication-type="other" id="oref0195">Prevention CfDCa. Overview of Testing for SARS-CoV-2 2020 [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html" id="intr0025">https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html</ext-link>.</mixed-citation></ref><ref id="bib0200"><mixed-citation publication-type="other" id="oref0200">Prevention CfDCa. Cases in the U.S. 2020 [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html" id="intr0030">https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html</ext-link>.</mixed-citation></ref><ref id="bib0205"><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name><surname>Rockl&#x000f6;v</surname><given-names>J.</given-names></name><name><surname>Sj&#x000f6;din</surname><given-names>H.</given-names></name><name><surname>Wilder-Smith</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures</article-title><source>J Travel Med</source><volume>27</volume><issue>3</issue><year>2020</year><pub-id pub-id-type="doi">10.1093/jtm/taaa030</pub-id></element-citation></ref><ref id="bib0210"><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>A.</given-names></name><name><surname>Sasaki</surname><given-names>T.</given-names></name><name><surname>Kato</surname><given-names>S.</given-names></name><name><surname>Hayashi</surname><given-names>M.</given-names></name><name><surname>Tsuzuki</surname><given-names>S.I.</given-names></name><name><surname>Ishihara</surname><given-names>T.</given-names></name></person-group><article-title>Natural history of asymptomatic SARS-CoV-2 infection</article-title><source>N Engl J Med</source><volume>383</volume><year>2020</year><fpage>885</fpage><lpage>886</lpage><pub-id pub-id-type="pmid">32530584</pub-id></element-citation></ref><ref id="bib0215"><mixed-citation publication-type="other" id="oref0215">State NY. Amid Ongoing COVID-19 Pandemic, Governor Cuomo Announces Results of Completed Antibody Testing Study of 15,000 People Showing 12.3 Percent of Population Has COVID-19 Antibodies 2020 [Available from: <ext-link ext-link-type="uri" xlink:href="https://www.governor.ny.gov/news/amid-ongoing-covid-19-pandemic-governor-cuomo-announces-results-completed-antibody-testing" id="intr0035">https://www.governor.ny.gov/news/amid-ongoing-covid-19-pandemic-governor-cuomo-announces-results-completed-antibody-testing</ext-link>.</mixed-citation></ref><ref id="bib0220"><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name><surname>Streeck</surname><given-names>H.</given-names></name><name><surname>Schulte</surname><given-names>B.</given-names></name><name><surname>Kuemmerer</surname><given-names>B.</given-names></name><name><surname>Richter</surname><given-names>E.</given-names></name><name><surname>Hoeller</surname><given-names>T.</given-names></name><name><surname>Fuhrmann</surname><given-names>C.</given-names></name></person-group><article-title>Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event</article-title><source>medRxiv</source><year>2020</year><comment>2020.2005.2004.20090076</comment></element-citation></ref><ref id="bib0225"><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>T.</given-names></name><name><surname>Weng</surname><given-names>D.</given-names></name></person-group><article-title>Estimating the effects of asymptomatic and imported patients on COVID-19 epidemic using mathematical modeling</article-title><source>J Med Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25939</pub-id></element-citation></ref><ref id="bib0230"><element-citation publication-type="journal" id="sbref0230"><person-group person-group-type="author"><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Tsang</surname><given-names>O.T.</given-names></name><name><surname>Leung</surname><given-names>W.S.</given-names></name><name><surname>Tam</surname><given-names>A.R.</given-names></name><name><surname>Wu</surname><given-names>T.C.</given-names></name><name><surname>Lung</surname><given-names>D.C.</given-names></name></person-group><article-title>Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study</article-title><source>Lancet Infect Dis</source><volume>20</volume><issue>5</issue><year>2020</year><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">32213337</pub-id></element-citation></ref><ref id="bib0235"><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name><surname>Velavan</surname><given-names>T.P.</given-names></name><name><surname>Pollard</surname><given-names>A.J.</given-names></name><name><surname>Kremsner</surname><given-names>P.G.</given-names></name></person-group><article-title>Herd immunity and vaccination of children for COVID19</article-title><source>Int J Infect Dis</source><volume>98</volume><year>2020</year><fpage>14</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">32585285</pub-id></element-citation></ref><ref id="bib0240"><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name><surname>Wambier</surname><given-names>C.G.</given-names></name><name><surname>Goren</surname><given-names>A.</given-names></name><name><surname>Va&#x000f1;o-Galv&#x000e1;n</surname><given-names>S.</given-names></name><name><surname>Ramos</surname><given-names>P.M.</given-names></name><name><surname>Ossimetha</surname><given-names>A.</given-names></name><name><surname>Nau</surname><given-names>G.</given-names></name></person-group><article-title>Androgen sensitivity gateway to COVID-19 disease severity</article-title><source>Drug Dev Res</source><year>2020</year></element-citation></ref><ref id="bib0245"><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>C.</given-names></name><name><surname>Wong</surname><given-names>Y.K.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Adegnika</surname><given-names>A.A.</given-names></name><name><surname>Kremsner</surname><given-names>P.G.</given-names></name></person-group><article-title>Preparedness is essential for malaria-endemic regions during the COVID-19 pandemic</article-title><source>Lancet</source><volume>395</volume><issue>10230</issue><year>2020</year><fpage>1094</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">32192582</pub-id></element-citation></ref><ref id="bib0250"><element-citation publication-type="journal" id="sbref0250"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W.E.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Chiew</surname><given-names>C.J.</given-names></name><name><surname>Yong</surname><given-names>S.E.</given-names></name><name><surname>Toh</surname><given-names>M.P.</given-names></name><name><surname>Lee</surname><given-names>V.J.</given-names></name></person-group><article-title>Presymptomatic transmission of SARS-CoV-2-Singapore, January 23-March 16, 2020</article-title><source>MMWR Morb Mortal Wkly Rep</source><volume>69</volume><issue>14</issue><year>2020</year><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">32271722</pub-id></element-citation></ref><ref id="bib0255"><element-citation publication-type="book" id="sbref0255"><person-group person-group-type="author"><name><surname>WHO</surname></name></person-group><chapter-title>Clinical Management of COVID-19: Interim Guidance</chapter-title><comment>May 27</comment><year>2020</year></element-citation></ref><ref id="bib0260"><element-citation publication-type="journal" id="sbref0260"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Long</surname><given-names>D.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name></person-group><article-title>Duration of SARS-CoV-2 viral RNA in asymptomatic carriers</article-title><source>Crit Care</source><volume>24</volume><issue>1</issue><year>2020</year><fpage>245</fpage><pub-id pub-id-type="pmid">32448332</pub-id></element-citation></ref><ref id="bib0265"><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Gui</surname><given-names>X.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name></person-group><article-title>Comparison of clinical characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China</article-title><source>JAMA Netw Open</source><volume>3</volume><issue>5</issue><year>2020</year><object-id pub-id-type="publisher-id">e2010182</object-id></element-citation></ref><ref id="bib0270"><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Rong</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Deng</surname><given-names>P.</given-names></name></person-group><article-title>Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster</article-title><source>Int J Infect Dis</source><volume>94</volume><year>2020</year><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">32247826</pub-id></element-citation></ref><ref id="bib0275"><element-citation publication-type="journal" id="sbref0275"><person-group person-group-type="author"><name><surname>Yongchen</surname><given-names>Z.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name></person-group><article-title>Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients</article-title><source>Emerg Microbes Infect</source><volume>9</volume><issue>1</issue><year>2020</year><fpage>833</fpage><lpage>836</lpage><pub-id pub-id-type="pmid">32306864</pub-id></element-citation></ref><ref id="bib0280"><element-citation publication-type="journal" id="sbref0280"><person-group person-group-type="author"><name><surname>Younes</surname><given-names>N.</given-names></name><name><surname>Al-Sadeq</surname><given-names>D.W.</given-names></name><name><surname>Al-Jighefee</surname><given-names>H.</given-names></name><name><surname>Younes</surname><given-names>S.</given-names></name><name><surname>Al-Jamal</surname><given-names>O.</given-names></name><name><surname>Daas</surname><given-names>H.I.</given-names></name></person-group><article-title>Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2</article-title><source>Viruses</source><volume>12</volume><issue>6</issue><year>2020</year><pub-id pub-id-type="doi">10.3390/v12060582</pub-id></element-citation></ref><ref id="bib0285"><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name><surname>Zang</surname><given-names>R.</given-names></name><name><surname>Gomez Castro</surname><given-names>M.F.</given-names></name><name><surname>McCune</surname><given-names>B.T.</given-names></name><name><surname>Zeng</surname><given-names>Q.</given-names></name><name><surname>Rothlauf</surname><given-names>P.W.</given-names></name><name><surname>Sonnek</surname><given-names>N.M.</given-names></name></person-group><article-title>TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes</article-title><source>Sci Immunol</source><volume>5</volume><issue>47</issue><year>2020</year></element-citation></ref><ref id="bib0290"><element-citation publication-type="journal" id="sbref0290"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name></person-group><article-title>Asymptomatic carriers of COVID-19 as a concern for disease prevention and control: more testing, more follow-up</article-title><source>Biosci Trends</source><volume>14</volume><issue>3</issue><year>2020</year><fpage>206</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">32321904</pub-id></element-citation></ref><ref id="bib0295"><element-citation publication-type="journal" id="sbref0295"><person-group person-group-type="author"><name><surname>Zhen-Dong</surname><given-names>Y.</given-names></name><name><surname>Gao-Jun</surname><given-names>Z.</given-names></name><name><surname>Run-Ming</surname><given-names>J.</given-names></name><name><surname>Zhi-Sheng</surname><given-names>L.</given-names></name><name><surname>Zong-Qi</surname><given-names>D.</given-names></name><name><surname>Xiong</surname><given-names>X.</given-names></name></person-group><article-title>Clinical and transmission dynamics characteristics of 406 children with coronavirus disease 2019 in China: a review</article-title><source>J Infect</source><volume>81</volume><issue>2</issue><year>2020</year><fpage>e11</fpage><lpage>e15</lpage><pub-id pub-id-type="pmid">32360500</pub-id></element-citation></ref><ref id="bib0300"><element-citation publication-type="journal" id="sbref0300"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Lei</surname><given-names>C.</given-names></name></person-group><article-title>Viral dynamics in asymptomatic patients with COVID-19</article-title><source>Int J Infect Dis</source><volume>96</volume><year>2020</year><fpage>288</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">32437933</pub-id></element-citation></ref><ref id="bib0305"><element-citation publication-type="journal" id="sbref0305"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Bloxham</surname><given-names>C.J.</given-names></name><name><surname>Hulme</surname><given-names>K.D.</given-names></name><name><surname>Sinclair</surname><given-names>J.E.</given-names></name><name><surname>Tong</surname><given-names>Z.W.M.</given-names></name><name><surname>Steele</surname><given-names>L.E.</given-names></name></person-group><article-title>Children are unlikely to have been the primary source of household SARS-CoV-2 infections</article-title><source>medRxiv</source><year>2020</year><comment>2020.2003.2026.20044826</comment></element-citation></ref><ref id="bib0310"><element-citation publication-type="journal" id="sbref0310"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>L.</given-names></name><name><surname>Ruan</surname><given-names>F.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Liang</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Hong</surname><given-names>Z.</given-names></name></person-group><article-title>SARS-CoV-2 viral load in upper respiratory specimens of infected patients</article-title><source>N Engl J Med</source><volume>382</volume><issue>12</issue><year>2020</year><fpage>1177</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">32074444</pub-id></element-citation></ref></ref-list></back></article>